Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.79 |
| ▸ | GSPT1 | P15170 | 5/20 | 0.79 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.79 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 6/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62187 | 0.93 | CRBN (0.82) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413700 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1403650 | 0.92 | CRBN (0.79) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL61816 | 0.91 | CRBN (0.81) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23900555 | 0.90 | CRBN (0.82) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL61099 | 0.89 | CRBN (0.83) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL61785 | 0.89 | CRBN (0.75) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413606 | 0.89 | CRBN (0.80) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL62578 | 0.89 | CRBN (0.80) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL29360673 | 0.89 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022254377-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2022-12-08 | — | — | WO | disclosed |